CHMP party conditionally approves CTI's Pixuvri: also OKs GSK's Nimenrix, Prostrakan's Sancuso
This article was originally published in Scrip
Executive Summary
The Committee for Human Medicinal Products (CHMP) has announced the outcomes of its 13-16 February 2012 deliberations, recommending the approval of GlaxoSmithKline meningococcal vaccine, Nimenrix (scripintelligence.com, 17 February 2012), and Prostrakan’s adjunct antinausea patch Sancuso (granisetron; scripintelligence.com, 17 February 2012).